265 filings
Page 6 of 14
8-K
xu69n7zmell
18 Jan 17
Immunomedics Highlights Expanded Pipeline Positioning Company for Sustained Value Creation
12:00am
8-K
twgu6uwwl7ipbki 0gku
18 Jan 17
Immunomedics Announces New Data for IMMU-132 at Investor R&D Day
12:00am
8-K
a2trcv gt70jlp4ein
12 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
b3fda m7r5airxd
9 Jan 17
Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan
12:00am
8-K
28vr9
12 Dec 16
Regulation FD Disclosure
12:00am
8-K
eqrxc2c21zu a7n
28 Nov 16
Immunomedics Postpones 2016 Annual Meeting of Stockholders
12:00am
8-K
zgkw qunt3uz9b4mnop
2 Nov 16
Immunomedics Announces First Quarter Fiscal 2017 Results and Clinical Program Developments
12:00am
8-K
ivuapm2j
18 Oct 16
Departure of Directors or Certain Officers
12:00am
8-K
84m9d7j2l28sr8 bnm0w
12 Oct 16
Immunomedics Announces Closing of $30 Million Financing
12:00am
8-K
6hb8ug43im 46
11 Oct 16
Immunomedics Announces $30 Million Financing
12:00am
8-K
4h23c560edmaovew2r
23 Sep 16
Departure of Directors or Certain Officers
12:00am
8-K
oxa7l
17 Aug 16
Immunomedics Announces Fiscal 2016 Results and Clinical Program Developments
12:00am
8-K
lhrvp1 nal8j0m7
21 Jun 16
Immunomedics Appoints Michael R. Garone as New Chief Financial Officer
12:00am
8-K
elds6pzrh
11 May 16
Other Events
12:00am
8-K
ce62z
4 May 16
Immunomedics Announces Third Quarter Fiscal 2016 Results and Clinical Program Developments
12:00am
8-K
8s2ysyhkkb26
14 Mar 16
Immunomedics Provides Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients With Advanced Pancreatic Cancer
12:00am
8-K
6atvn7d54
29 Feb 16
Immunomedics Announces Termination of Epratuzumab Licensing Agreement With UCB
12:00am
8-K
a79ue
3 Feb 16
Immunomedics Announces Second Quarter Fiscal 2016 Results and Clinical Program Developments
12:00am
8-K
enz7l9y6htnn0zd5hr8j
2 Dec 15
Submission of Matters to a Vote of Security Holders
12:00am
8-K
p3ler5cqxzqe ydzf
30 Nov 15
Entry into a Material Definitive Agreement
12:00am